AI Summary
✦ ClarthaConcord Biotech is a biopharma company manufacturing and selling APIs and formulations in India and overseas. Fermentation-based APIs serve immunosuppressant, antibacterial, oncology, and antifungal therapies, while formulations include tacrolimus, mycophenolate, everolimus, and related products. Recent revenue growth of 26% in Q1 FY2027 suggests improved demand, supporting the company’s improving margin trend. Profit declined 29.8% year-on-year despite improving margins, indicating earnings pressure beneath recent quarterly momentum. With debt-to-equity of 0.12, Concord is deleveraged, though ROE is unavailable for assessing capital efficiency. At 47 times earnings, the stock appears rich relative to recent negative revenue and profit growth. The key open question is whether oncology and immunosuppressant demand can sustain the latest acceleration.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 5 analysts
Fundamentals
Fundamentals institutional score is 97 using growth durability 97.3.
Valuation
Valuation institutional score is 81 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 63 using mean target upside 8.5%; dispersion penalty 11.1; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 26 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and valuation provide support, while technical structure and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 3.5% below historical median. Valuation is declining — currently in the strongly undervalued zone (z-score: -0.26). Confidence: 79%.
Live forward EPS implies next-12-month EPS of ₹42.54. Applying the stock's normalized valuation corridor produces a fair range of ₹1,896.43 to ₹2,440.95, with base value near ₹2,165.29 (+51.5% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹42.54
Forward P/E
33.6x
Base Fair Value
₹2,165.29
Fair Range
₹1,896.43 - ₹2,440.95
Upside To Base
+51.5%
Estimate Source
Live forward EPS
Growth Estimate
+31.1%
5Y Average
52.05
Current
49.12
Overvalued
57.38
Undervalued
44.58
5Y Average
14.29
Current
13.49
Overvalued
15.67
Undervalued
12.57
5Y Average
37.94
Current
35.81
Overvalued
41.61
Undervalued
33.37
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.7x Premium | +17% vs avg | +51.8% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Premium | +17% vs avg | -25.8% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 36.3x Fair | -3% vs avg | +9.4% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.6x Fair | +3% vs avg | -15.4% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 40.0x Fair | +7% vs avg | +22.5% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.5x Fair | +3% vs avg | +30.0% |
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -17% vs avg | +22.8% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 27.6x Undervalued | -26% vs avg | +43.2% |
CONCORD BIOTECH LIMITED trades at a premium (49.1x vs peer avg 37.5x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include AKUMS DRUGS AND PHARMA L, BLUE JET HEALTHCARE LTD, GLENMARK PHARMACEUTICALS — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹261 CrJun 2026Latest net profit
₹61 CrJun 2026Latest EPS
₹5.85Jun 2026Net margin
33.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 261 |
| Expenses + | 123 | 143 | 135 | 185 | 135 | 174 | 146 | 239 | 143 | 157 | 176 | 204 | 173 |
| Operating Profit | 72 | 119 | 106 | 134 | 81 | 137 | 98 | 190 | 61 | 91 | 102 | 122 | 87 |
| OPM % | 37% | 45% | 44% | 42% | 38% | 44% | 40% | 44% | 30% | 37% | 37% | 38% | 33% |
| Other Income + | 7 | 8 | 8 | 11 | 10 | 10 | 15 | 9 | 14 | 13 | 7 | 16 | 13 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 19 | 18 |
| Profit before tax | 65 | 113 | 100 | 131 | 78 | 133 | 99 | 185 | 57 | 86 | 90 | 118 | 82 |
| Tax % | 25% | 25% | 26% | 26% | 25% | 26% | 25% | 23% | 26% | 26% | 25% | 24% | 26% |
| Net Profit + | 48 | 84 | 75 | 97 | 58 | 99 | 74 | 142 | 43 | 63 | 68 | 90 | 61 |
| EPS in Rs | 4.63 | 8.08 | 7.13 | 9.29 | 5.57 | 9.43 | 7.08 | 13.57 | 4.07 | 6.01 | 6.48 | 8.60 | 5.85 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome